Enveric Biosciences Yönetim

Yönetim kriter kontrolleri 3/4

Enveric Biosciences CEO'su Joseph Tucker, Sep2021 tarihinde atandı, in görev süresi 3.17 yıldır. in toplam yıllık tazminatı $ 577.07K olup, şirket hissesi ve opsiyonları dahil olmak üzere 78.1% maaş ve 21.9% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.33% ine doğrudan sahiptir ve bu hisseler € 13.23K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3.2 yıl ve 2.3 yıldır.

Anahtar bilgiler

Joseph Tucker

İcra Kurulu Başkanı

US$577.1k

Toplam tazminat

CEO maaş yüzdesi	78.1%
CEO görev süresi	3.2yrs
CEO sahipliği	0.3%
Yönetim ortalama görev süresi	3.2yrs
Yönetim Kurulu ortalama görev süresi	2.3yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Joseph Tucker'un ücretlendirmesi Enveric Biosciences'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	-US$11m
Mar 31 2024	n/a	n/a	-US$15m
Dec 31 2023	US$577k	US$451k	-US$17m
Sep 30 2023	n/a	n/a	-US$23m
Jun 30 2023	n/a	n/a	-US$23m
Mar 31 2023	n/a	n/a	-US$19m
Dec 31 2022	US$826k	US$362k	-US$19m
Sep 30 2022	n/a	n/a	-US$52m
Jun 30 2022	n/a	n/a	-US$52m
Mar 31 2022	n/a	n/a	-US$50m
Dec 31 2021	US$3m	US$92k	-US$49m

Tazminat ve Piyasa: Joseph 'ın toplam tazminatı ($USD 577.07K ) German pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 488.36K ).

Tazminat ve Kazançlar: Joseph 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Joseph Tucker (55 yo)

3.2yrs

Görev süresi

US$577,065

Tazminat

Dr. Joseph Tucker, Ph D., has been a Director of Enveric Biosciences, Inc. since September 16, 2021. Dr. Tucker has been the Chief Executive Officer of Enveric Biosciences, Inc. since September 16, 2021.D...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Joseph Tucker	CEO & Director	3.2yrs	US$577.07k	0.33% € 13.2k
Kevin Coveney	Chief Financial Officer	1.7yrs	US$435.31k	0.074% € 3.0k
Peter Facchini	Chief Innovation Officer	3.2yrs	US$282.06k	0.22% € 8.9k

3.2yrs

Ortalama Görev Süresi

60yo

Ortalama Yaş

Deneyimli Yönetim: SLZA 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.2 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Joseph Tucker	CEO & Director	3.2yrs	US$577.07k	0.33% € 13.2k
Michael Webb	Independent Chairman of the Board	2.4yrs	US$175.00k	0.54% € 21.5k
Sheila DeWitt	Independent Director	less than a year	Veri yok	0.31% € 12.5k
Stephen Stahl	Member of Scientific Advisory Board	2.3yrs	Veri yok	Veri yok
Frank Pasqualone	Independent Director	2.3yrs	US$57.50k	0.55% € 22.0k
Maurizio Fava	Chairman of Scientific Advisory Board	2.3yrs	Veri yok	Veri yok
Michael Liebowitz	Member of Scientific Advisory Board	2.3yrs	Veri yok	Veri yok
John Krystal	Member of Scientific Advisory Board	2.3yrs	Veri yok	Veri yok
Marcus Schabacker	Independent Non-Employee Director	3.9yrs	US$52.00k	0.54% € 21.7k
George Kegler	Independent Non-Employee Director	3.9yrs	US$59.00k	0.54% € 21.7k

2.3yrs

Ortalama Görev Süresi

64yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: SLZA 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilmiyor ( 2.3 yıllık ortalama görev süresi), bu da yeni bir yönetim kurulu olduğunu gösteriyor.

Enveric Biosciences Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

High number of new and inexperienced directors

Enveric Biosciences, Inc., Annual General Meeting, May 28, 2024

Enveric Biosciences, Inc., Annual General Meeting, Nov 02, 2023

High number of new and inexperienced directors

High number of new and inexperienced directors

High number of new and inexperienced directors

Recent updates

Enveric Biosciences Announces Positive Pharmacology and Safety Data for Lead Product, EB-003

New major risk - Financial position

Enveric Biosciences Announces Preclinical Results Confirming Potential of EB-003 to Be Dosed Orally

New major risk - Share price stability

Enveric Biosciences Regains Compliance with the Minimum Stockholders’ Equity Requirement for Continued Listing on the Nasdaq Capital Market Pursuant to Nasdaq Listing Rule 5550(b)(1)

Enveric Biosciences Receives Notification Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market Pursuant to Nasdaq Marketplace Rule 5550(a)(2)

New major risk - Financial position

High number of new and inexperienced directors

Enveric Biosciences, Inc., Annual General Meeting, May 28, 2024

New major risk - Shareholder dilution

Enveric Biosciences, Inc. has filed a Follow-on Equity Offering in the amount of $0.322453 million.

Enveric Biosciences Unveils Library of Preclinical Compounds Across Multiple Distinct Molecule Classes Targeting Mental Health Disorders

Enveric Biosciences Receives Notice from the Nasdaq Stock Market

New major risk - Share price stability

Enveric Biosciences Selects EB-003 as Lead Drug Candidate from EVM301 Series

Enveric Biosciences Selects Development Candidates from Evm301 Series Based on Potential to Minimize or Eliminate the Hallucinogenic Effect of Psychedelic-Derived Compounds

Enveric Biosciences Announces Manuscript Describing the Development of Lead Product Candidate, EB-373, to be Featured on the Cover of the Journal of Medicinal Chemistry

Enveric Biosciences Announces Manuscript Describing the Development of Lead Product Candidate, EB-373, to be Featured on the Cover of the Journal of Medicinal Chemistry

Enveric Biosciences Receives a Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market

Enveric Biosciences Initiates GLP Toxicology & Safety Pharmacology Studies for Lead Candidate EB-373

Enveric Biosciences, Inc., Annual General Meeting, Nov 02, 2023

Enveric Biosciences Completes Manufacturing of EB-373 to Supply Drug Material for Completion of Preclinical Program

High number of new and inexperienced directors

Enveric Biosciences, Inc. Reports Positive Results from Preclinical Studies Supporting Metabolic Profile of Lead Candidate EB-373

Enveric Biosciences Reports Positive Results from Animal Studies Demonstrating Oral Bioavailability and Well Tolerated Side Effect Profile for EB-373

Enveric Biosciences, Inc. Announces Development of Phase 1-Ready Formulation for EB-373 and Initiation of Scaled Up Manufacturing

Enveric Biosciences, Inc. Announces Manuscript Detailing the Development of Novel Psilocin Prodrugs for the Treatment of Anxiety and Other Mental Health Disorders

Enveric Biosciences, Inc. Receives Notice of Allowance from Uspto for Novel Prodrug of Psilocin

High number of new and inexperienced directors

High number of new and inexperienced directors

Enveric Biosciences, Inc. Advances Lead Candidate for the Treatment of Anxiety Disorders to IND-Enabling Studies

Enveric Biosciences, Inc., Annual General Meeting, Oct 28, 2022

Enveric Biosciences, Inc. Appoints Robert Dickey IV as Chief Financial Officer

Enveric Biosciences, Inc. Regains Compliance with Listing Rule 5550(a)(2) Letter from the Listing Qualifications Department of Nasdaq

Enveric Biosciences, Inc. Appoints New Independent Directors

Enveric Biosciences, Inc. announced that it expects to receive $5 million in funding

Enveric Biosciences Announces Formation of Scientific Advisory Board to Drive Further Growth of Next-Generation Mental Health Medicines

Enveric Biosciences, Inc. Announces Appointment of Frank Pasqualone to the Board of Directors

Enveric Biosciences Announces Management Appointments

High number of new and inexperienced directors

Enveric Biosciences, Inc. Expands Portfolio of Drug Development Candidates and Files New Provisional Patent Application

Enveric Biosciences Files Portfolio of Patent Applications for Tryptamine-Based Molecules

Enveric Biosciences, Inc. announces development of EV104a and EV104b

Enveric Biosciences, Inc. (NasdaqCM:ENVB) entered into a definitive agreement to acquire MagicMed Industries Inc.

Enveric Biosciences, Inc. announced delayed annual 10-K filing

Enveric Biosciences, Inc. Appoints Dr. Douglas D. Lind to Company's Board of Directors

Enveric Biosciences, Inc. (NasdaqCM:ENVB) completed the acquisition of Exclusive and perpetual license for Diverse Biotech novel molecules from Diverse Biotech, Inc.

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş